Leading Global AH Companies Capitalizing Patent Cliff – Basis ANDA Filings and Approvals

The global animal health industry is approaching an unprecedented $15 billion veterinary patent cliff spanning 2026 to 2030. While human pharmaceutical patent cliffs routinely dominate headers, the companion animal and livestock sectors are entering a golden era for generic manufacturers as top-selling parasiticides, monoclonal antibodies, and chronic care treatments lose exclusivity.

Navigating this veterinary shift requires a different playbook than human pharma due to distinct regulatory pathways, fragmented distribution networks, and out-of-pocket consumer dynamics.

Following is a List of 7 Leading Animal Health Companies which are well suited to capitalize on the upcoming USD 15 Bn Veterinary Drugs’ Patent Cliff

1. Dechra Pharmaceuticals (Freya Bidco / EQT Group)

• Overview: A leader in human-to-veterinary repurposing and differentiated generics, Dechra operates extensively across North America and Europe.

• Manufacturing & R&D Hubs:

  • USA: Overland Park, KS (US HQ); Fort Worth, TX.

  • Europe: Bladel, Netherlands; Skipton, UK; Zagreb, Croatia.

• Recent Major ANADA / FDA Approvals:

  • Emeprev™ (maropitant citrate) Injectable Solution: Bioequivalent generic equivalent to Zoetis’ pioneer antiemetic Cerenia® for dogs and cats, featuring an upgraded local-anesthetic preservative matrix to reduce injection-site pain.

  • CosACTHen® (cosyntropin injection): Diagnostic injectable for canine adrenal testing (Cushing’s/Addison’s).

2. Virbac

• Overview: France-based Virbac combines generic therapeutics with proprietary delivery systems across companion and food-animal sectors.

• Manufacturing & R&D Hubs:

  • Europe: Carros & Magny-en-Vexin, France.

  • Americas: Bridgeton, MO, USA; Guadalajara, Mexico; São Paulo, Brazil.

  • Asia-Pacific: Penrith, Australia; Punjab, India.

• Recent Major ANADA / FDA Approvals:

  • Firocoxib Oral Paste & Chewables (ANADA 200-805): Bioequivalent pain management options for equine and canine markets (Previcox® / Equioxx® generic equivalents).

  • Amoxicillin/Clavulanate Potassium Bioequivalents: Oral suspensions targeting dermatological and soft-tissue bacterial infections (Clavamox® generic equivalents).

3. Norbrook Laboratories

• Overview: Headquartered in Northern Ireland, Norbrook holds one of the largest portfolios of veterinary generic FDA approvals globally, specializing in production-animal antibiotics and companion-animal NSAIDs.

• Manufacturing & R&D Hubs:

  • UK & Europe: Newry, Northern Ireland (Sterile liquid and oral dose complexes).

  • USA: Overland Park, KS.

• Recent Major ANADA / FDA Approvals:

  • Tulathromycin Injectables (Generic Draxxin®): Generic macrolide injectables for Bovine Respiratory Disease (BRD) and Swine Respiratory Disease (SRD).

  • Carprieve® & Loxicom® Extensions: Palatability-enhanced chewable tablets for carprofen and meloxicam (Rimadyl® and Metacam® equivalents).

4. Bimeda Animal Health

• Overview: Privately owned global manufacturer focused on high-volume generic production-animal pharmaceuticals, intramammaries, parasiticides, and equine health products.

• Manufacturing & R&D Hubs:

  • North America: Le Sueur, MN, USA; Cambridge, ON, Canada.

  • Europe: Dublin, Ireland; Liverpool, UK.

  • Latin America & Asia: São Paulo, Brazil; Shijiazhuang, China.

• Recent Major ANADA / FDA Approvals:

  • Ivermectin + Praziquantel Equine Paste (ANADA 200-636): Broad-spectrum anthelmintic paste targeting equine bots, tapeworms, and nematodes.

  • KetoMed™ (ketoprofen injectable, ANADA 200-625): Control of pyrexia associated with Bovine Respiratory Disease (BRD) in cattle.

5. Chanelle Pharma

• Overview: Headquartered in Loughrea, County Galway, Ireland, Chanelle Pharma (acquired by private equity firm Exponent in 2024) is one of the world’s most versatile manufacturers and out-licensing partners for generic human and animal pharmaceuticals. Holding over 3,000 animal health licenses worldwide (and the largest portfolio of veterinary licenses in the EU), Chanelle develops bioequivalent products and contracts white-label generic formulations directly to major global animal health distributors.

• Manufacturing & R&D Hubs:

  • Ireland: Loughrea, Co. Galway (17-acre global HQ featuring 3 manufacturing plants, an FDA-approved dedicated Spot-On topical facility, and 4 specialized R&D centers).

  • Middle East: Amman, Jordan (R&D and regional manufacturing).

• Recent Major ANADA & Global Approvals:

  • PARASEDGE™ Multi for Dogs / Cats (ANADA 200-700): A bioequivalent topical spot-on solution (imidacloprid + moxidectin) matching Elanco’s Advantage Multi® for heartworm prevention, microfilaria treatment, and flea control.

  • ANIMEC PLUS (ivermectin and clorsulon) Injection (ANADA 200-506): Bioequivalent antiparasitic injectable targeting liver flukes, roundworms, and lungworms in cattle (competing with Boehringer Ingelheim’s Ivomec® Plus).

  • Generic Spot-On Portfolio Extensions: Continuous EU and FDA filings for topical fipronil, permethrin, and moxidectin formulations produced in their dedicated FDA-certified Spot-On manufacturing site.

6. Cronus Pharma

• Overview: A fast-growing specialized generic player focusing on high-complexity sterile injectables and specialized companion animal oral solids.

• Manufacturing & R&D Hubs:

  • USA: East Brunswick, NJ (US Commercial HQ).

  • India: Hyderabad, Telangana (Sterile injectable and oral solid dosage production site).

• Recent Major ANADA / FDA Approvals:

  • EnroPro™ (Enrofloxacin Oral Tablets, ANADA 200-835, July 2026): Bioequivalent fluoroquinolone equivalent to Baytril® for companion animals.

  • Cropamezole™ (atipamezole hydrochloride, ANADA 200-753): Bioequivalent injectable reversing agent to Antisedan® used in clinical sedation protocols.

7. Felix Pharmaceuticals (Felixvet)

• Overview: Headquartered commercially in Kansas City, MO, with global clinical and R&D operations based out of Dublin (Ireland) and India, Felix Pharmaceuticals (operating commercially as Felixvet) is a pure-play generic companion animal health company. Holding over 20 FDA ANADA approvals and a rapid pipeline of ~70 drugs in active development, Felixvet specifically targets high-volume small-animal therapeutics, antiemetics, NSAIDs, and antimicrobials.

• Manufacturing & R&D Hubs:

  • USA: Kansas City, MO (US Commercial HQ).

  • Europe: Dublin, Ireland (Regulatory & Global Holdings).

  • India: Gurgaon & Hyderabad (R&D centers and sterile/oral dosage manufacturing sites).

• Recent Major ANADA & FDA Approvals:

  • Methimazole Oral Solution (ANADA 200-860, July 2026): Generic equivalent expanding feline hyperthyroidism care following their earlier landmark approval for Methimazole Coated Tablets (ANADA 200-814), the first generic oral tablet bioequivalent to Dechra’s Felimazole®.

  • Nitenpyram Tablets (ANADA 200-858, June 2026): Bioequivalent oral fast-acting flea treatment (equivalent to Elanco’s Capstar®).

  • Clindamycin Hydrochloride Tablets (ANADA 200-813): Bioequivalent to Zoetis’ Antirobe® capsules; Felixvet successfully petitioned the FDA for a dosage form change (capsule-to-tablet) under a suitability petition to improve clinical convenience.

  • Carprofen Flavored Tablets (ANADA 200-767) & Firocoxib Chewables: Expanding bioequivalent small-animal pain management options directly competing against Zoetis’ Rimadyl® and Boehringer Ingelheim’s Previcox®.